These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33872641)

  • 1. Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis.
    Sharabiani M; Clementel E; Andratschke N; Collette L; Fortpied C; Grégoire V; Overgaard J; Willmann J; Hurkmans C
    Radiother Oncol; 2021 Aug; 161():35-39. PubMed ID: 33872641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
    Deneuve S; Bastogne T; Duclos M; Mirjolet C; Bois P; Bachmann P; Nokovitch L; Roux PE; Girodet D; Poupart M; Zrounba P; Claude L; Ferella L; Iacovelli NA; Foray N; Rancati T; Pereira S
    Tumori; 2023 Apr; 109(2):173-185. PubMed ID: 35578746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy.
    Beetz I; Schilstra C; van Luijk P; Christianen ME; Doornaert P; Bijl HP; Chouvalova O; van den Heuvel ER; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):94-100. PubMed ID: 22169766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy.
    Dean JA; Wong KH; Welsh LC; Jones AB; Schick U; Newbold KL; Bhide SA; Harrington KJ; Nutting CM; Gulliford SL
    Radiother Oncol; 2016 Jul; 120(1):21-7. PubMed ID: 27240717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.
    Hansen CR; Friborg J; Jensen K; Samsøe E; Johnsen L; Zukauskaite R; Grau C; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
    Acta Oncol; 2019 Oct; 58(10):1410-1415. PubMed ID: 31432744
    [No Abstract]   [Full Text] [Related]  

  • 6. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort.
    Blanchard P; Wong AJ; Gunn GB; Garden AS; Mohamed ASR; Rosenthal DI; Crutison J; Wu R; Zhang X; Zhu XR; Mohan R; Amin MV; Fuller CD; Frank SJ
    Radiother Oncol; 2016 Dec; 121(3):381-386. PubMed ID: 27641784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach.
    Christianen ME; van der Schaaf A; van der Laan HP; Verdonck-de Leeuw IM; Doornaert P; Chouvalova O; Steenbakkers RJ; Leemans CR; Oosting SF; van der Laan BF; Roodenburg JL; Slotman BJ; Bijl HP; Langendijk JA
    Radiother Oncol; 2016 Feb; 118(2):298-303. PubMed ID: 26700602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of a normal tissue complication probability model for radiation-induced hypothyroidism in an independent cohort.
    Rønjom MF; Brink C; Bentzen SM; Hegedüs L; Overgaard J; Petersen JB; Primdahl H; Johansen J
    Acta Oncol; 2015; 54(9):1301-9. PubMed ID: 26248025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.
    Dankers FJWM; Wijsman R; Troost EGC; Tissing-Tan CJA; Kwint MH; Belderbos J; de Ruysscher D; Hendriks LE; de Geus-Oei LF; Rodwell L; Dekker A; Monshouwer R; Hoffmann AL; Bussink J
    Radiother Oncol; 2018 Nov; 129(2):249-256. PubMed ID: 30241789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the SORG Algorithm Predict 5-year Survival in Patients with Chondrosarcoma? An External Validation.
    Bongers MER; Thio QCBS; Karhade AV; Stor ML; Raskin KA; Lozano Calderon SA; DeLaney TF; Ferrone ML; Schwab JH
    Clin Orthop Relat Res; 2019 Oct; 477(10):2296-2303. PubMed ID: 31107338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
    Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating a benchmarking tool for audit of early outcomes after operations for head and neck cancer.
    Tighe D; Sassoon I; McGurk M
    Ann R Coll Surg Engl; 2017 Apr; 99(4):299-306. PubMed ID: 27917662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Normal Tissue Complication Probability Model for Lymphedema After Radiation Therapy in Breast Cancer.
    Park YI; Chang JS; Ko H; Im SH; Kim JS; Byun HK; Kim YB; Jung W; Kim K; Hong CS
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1218-1225. PubMed ID: 36739918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a post operative complication risk prediction algorithm in a non-head and neck squamous cell carcinoma cohort.
    Reeves S; Tarmohamed O; Babbra A; Tighe D
    Br J Oral Maxillofac Surg; 2022 Sep; 60(7):904-909. PubMed ID: 35346521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent validation of a dysphagia dose response model for the selection of head and neck cancer patients to proton therapy.
    Kalendralis P; Sloep M; Moni George N; Snel J; Veugen J; Hoebers F; Wesseling F; Unipan M; Veening M; Langendijk JA; Dekker A; van Soest J; Fijten R
    Phys Imaging Radiat Oncol; 2022 Oct; 24():47-52. PubMed ID: 36158240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk.
    Dean JA; Welsh LC; Wong KH; Aleksic A; Dunne E; Islam MR; Patel A; Patel P; Petkar I; Phillips I; Sham J; Schick U; Newbold KL; Bhide SA; Harrington KJ; Nutting CM; Gulliford SL
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):263-273. PubMed ID: 28057404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalizability assessment of head and neck cancer NTCP models based on the TRIPOD criteria.
    Sharabiani M; Clementel E; Andratschke N; Hurkmans C
    Radiother Oncol; 2020 May; 146():143-150. PubMed ID: 32155505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTCP Modeling for High-Grade Temporal Radionecroses in a Large Cohort of Patients Receiving Pencil Beam Scanning Proton Therapy for Skull Base and Head and Neck Tumors.
    Schröder C; Köthe A; De Angelis C; Basler L; Fattori G; Safai S; Leiser D; Lomax AJ; Weber DC
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):448-455. PubMed ID: 35124132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.